IJGC Podcast

Post-PARP Myeloid Neoplasms with Giuseppe Caruso

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Giuseppe Caruso discuss post-PARP myeloid neoplasms. Dr. Caruso is a fifth-year resident in Obstetrics and Gynecology and a first-year fellow of the PhD in “Network Oncology and Precision Medicine” at Sapienza University of Rome in Italy. Over the past year, he has been attending the Department of Gynecologic Oncology at the European Institution of Oncology (Milan) under the mentorship of Professor Nicoletta Colombo and has now started his research fellowship period at Mayo Clinic (Rochester) under the supervision of Professor William Cliby. His main interest areas are gynecologic oncology, personalized oncology, and clinical research.
Highlights:
- Myeloid neoplasms post PARPi in patients with ovarian cancer are gradually emerging as life-threatening late toxicities and should not be underestimated.
- The first two years of PARPi exposure are the critical window of onset and persistent cytopenia has been recognized as an early warning sign.
- Active surveillance, differential diagnosis, and prompt hematological referral are crucial.
- PARPi are recommended in the first line also to improve the risk-benefit ratio.
- PARPi should be used cautiously in patients with a higher baseline risk and/or those who are less likely to have a significant benefit.

ESGO-ESTRO-ESP Guidelines for Cervical Cancer 2023 with David Cibula

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. David Cibula to discuss the 2023 ESGO-ESTRO-ESP Guidelines for Cervical Cancer. Dr. Cibula is the Chair of the Department of Obstetrics and Gynecology at the General Faculty Hospital in Prague, Professor at the First Medical Faculty of the Charles University, Chair of the Central and Eastern European Gynaecologic Oncology Group (CEEGOG), member of the Strategic group of the ENGOT (European Network for Gynaecological Oncological Trial Groups) as well as a Former ESGO president.
Highlights:
- Multidisciplinary clinical practice guidelines developed jointly by ESGO/ESTRO/ESP in the field of gynaecological oncology, radiation oncology and pathology.
- Guidelines cover the management of all stages of cervical cancer, including separate sections dedicated to pathology reporting and management in pregnancy.
- The guidelines include recommendations, algorithms, and summaries of recent evidence published as supplements.

Back by Demand: Updates on PARPi Ovarian Cancer

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Giuseppe Caruso and Prof. Nicoletta Colombo to discuss updates on PARPi in ovarian cancer. Dr. Caruso is a fifth-year resident in Obstetrics and Gynecology and a first-year fellow of the PhD in “Network Oncology and Precision Medicine” at the Sapienza University of Rome in Italy. Over the past year, he has been attending the Department of Gynecologic Oncology at the European Institution of Oncology (Milan) and had the huge opportunity to follow the clinical, surgical and research activities of an international center of excellence, under the mentorship of Prof. Nicoletta Colombo and Prof. Giovanni D. Aletti. His main interest areas are gynecologic oncology, personalized oncology, clinical research, and medical writing. Prof. Nicoletta Colombo is Chair of Gynecology Program and Director of the Ovarian Cancer Centre at the European Institute of Oncology in Milan. Principal investigators of several international clinical trials and author of several publications, she was President of ESGO and Chair of the ESMO-ESGO-ESTRO Consensus Conference in endometrial cancer (2015) and the ESMO-ESGO Consensus Conference in ovarian Cancer (2018). In 2020, Prof. Colombo received the IGCS Lifetime Achievement Award in recognition of her work in gynecological oncology.
Highlights:
- PARPi should be preferred in the upfront setting for both efficacy and safety reasons.
- Mutational status and platinum response are key factors for personalizing the maintenance treatment.
- Identifying better predictors of resistance to platinum and PARPi is an unmet need.
- PARPi combinations could become a strategy for overcoming PARPi resistance.
- The best treatment algorithm after PARPi progression needs prospective validation.

Intraoperative Imaging with OTL38 in Ovarian Cancer

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Janos L. Tanyi to discuss intraoperative imaging with OTL38 in ovarian cancer. Dr. Tanyi is an associate professor in the Department of Obstetrics and Gynecology at The University of Pennsylvania. He developed an advanced immunotherapy program that allows patients’ own immune cells to recognize and kill their tumor; a gene-engineered T cell approach. Dr. Tanyi has a broad background in immunotherapy, cancer immunology, molecular genetics and clinical expertise in gynecologic oncology. He has the frontline experience in ovarian cancer immunotherapy as he is the primary PI for both the ovarian cancer vaccine and adoptive T cell transfer trials at University of Pennsylvania. At Penn, he has fostered the establishment of a rich translational research environment focused on ovarian cancer. Furthermore, Dr. Tanyi led the Phase 2 and 3 trials evaluating the efficacy and safety of Pafolacianine Sodium combined with intraoperative molecular imaging during cytoreductive surgery of ovarian cancer.
Highlights:
- It is well known that the extent of residual disease after surgery is negatively correlated with patient survival in ovarian cancer. To achieve R0 complete cytoreduction remains the goal of surgery. In this phase III study, it was evaluated whether Cytalux, would identify cancer lesions not identified by the surgeon by white light visual inspection or palpation.
- During this phase 3 trial, one or more additional cancer lesions were identified in approximately 33% of patients using of Cytalux with near-infrared imaging which was not detected by white light visual inspection and manual palpation.
- The intraoperative use of Cytalux with near-infrared imaging can be a good adjunct to current surgical approaches in identifying additional cancer lesions during cytoreductive surgery.

Laura Chambers - Low-risk Population in Advanced Ovarian Cancer

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Laura Chambers to discuss the low-risk population in advanced ovarian cancer. Laura Chambers, DO is an Assistant Professor in the Division of Gynecologic Oncology at The James Cancer Center at The Ohio State University.
Highlights:
- Discuss historical perspectives of low and high-risk ovarian cancer, and how this has been analyzed in contemporary trials
- Review of contemporary trials for PARPi and Bevacizumab maintenance in women with advanced ovarian cancer
- Data obtained through un-powered sub-analysis from randomized clinical trials is hypothesis generating and care must be exercised in applying this to patient cohorts

Reviewing the March Special Issue with Giulio Bonaldo and Jennifer Davies-Oliveira

In this episode of the IJGC Podcast, Editorial Fellows, Giulio Bonaldo and Jennifer Davies-Oliveira, discuss the contents of the March Special issue of IJGC.

Reviewing the February Issue with Núria Agustí and Ryan Kahn

In this episode of the IJGC Podcast, Editorial Fellows, Núria Agustí and Ryan Kahn, discuss the contents of the February issue of IJGC.

Updates on PARPi in Ovarian Cancer

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Giuseppe Caruso and Prof. Nicoletta Colombo to discuss updates on PARPi in ovarian cancer. Dr. Caruso is a fifth-year resident in Obstetrics and Gynecology and a first-year fellow of the PhD in “Network Oncology and Precision Medicine” at the Sapienza University of Rome in Italy. Over the past year, he has been attending the Department of Gynecologic Oncology at the European Institution of Oncology (Milan) and had the huge opportunity to follow the clinical, surgical and research activities of an international center of excellence, under the mentorship of Prof. Nicoletta Colombo and Prof. Giovanni D. Aletti. His main interest areas are gynecologic oncology, personalized oncology, clinical research, and medical writing.
Prof. Nicoletta Colombo is Chair of Gynecology Program and Director of the Ovarian Cancer Centre at the European Institute of Oncology in Milan. Principal investigators of several international clinical trials and author of several publications, she was President of ESGO and Chair of the ESMO-ESGO-ESTRO Consensus Conference in endometrial cancer (2015) and the ESMO-ESGO Consensus Conference in ovarian Cancer (2018). In 2020, Prof. Colombo received the IGCS Lifetime Achievement Award in recognition of her work in gynecological oncology.
Highlights:
- PARPi should be preferred in the upfront setting for both efficacy and safety reasons.
- Mutational status and platinum response are key factors for personalizing the maintenance treatment.
- Identifying better predictors of resistance to platinum and PARPi is an unmet need.
- PARPi combinations could become a strategy for overcoming PARPi resistance.
- The best treatment algorithm after PARPi progression needs prospective validation.

KELIM Validation: GOG 218 with Benoit You

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Benoit You to discuss KELIM validation. Dr. You is a French medical oncologist at Lyon University Hospital, specialized in gynecological cancers, and the head of the drug development program of his institution (CITOHL-EPSILYON). Morever, he is the Director of a university research team involved in pharmacokinetics, and modeling analyses of the kinetics of serum tumor markers (EA 3738 CICLY). He is an active member of the French GINECO group, of the European ENGOT group, and of the international GCIG group.
Highlights:
- KELIM is the modeled CA-125 decline rate during the first 3 cycles of adjuvant or neo-adjuvant chemotherapy in first-line setting
- It is a pragmatic indicator of the tumor intrinsic chemosensitivity, easily calculable online on https://www.biomarker-kinetics.org
- KELIM is helpful to surgeons to anticipate the feasibility/complexity of complete interval debulking surgery after neo-adjuvant chemotherapy
- The analyses of ICON-7 and GOG-0218 trial datasets reproducibly showed that only the patients with unfavorable KELIM score - KELIM may be a complementary tool to HRD status to select the best maintenance treatment in first-line setting, especially in patients with HRP cancer : PARP inhibitor expected to be effective in the case of favorable KELIM score ≥ 1.0 ; bevacizumab expected to be effective in the case of unfavorable KELIM score

LESSER Trial With Vandré Carneiro And Glauco Baiocchi

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Drs. Vandré Carneiro and Glauco Baiocchi to discuss the LESSER trial. Dr. Carneiro is the head of the Department of Gynecologic Oncology at the Instituto de Medicina Integral Professor Fernando Figueira (IMIP). He is also Director of the Department of the Hereditary Cancer Program of Hospital de Cancer de Pernambuco. Dr. Baiocchi is the head of the Department of Gynecologic Oncology at the AC Camargo Cancer Center. He is also the president of the Brazilian Gynecologic Oncology Group – EVA Group.
Highlights:
- Hysterectomy is safe and potentially non-inferior to modified radical hysterectomy in early-stage cervical cancer.
- The LESSER supports simple hysterectomy as a substitute for radical hysterectomy in patients with cervical cancer ≤2 cm.
- The SHAPE trial will provide more concrete data on the role of simple hysterectomy for early-stage cervical cancer.